Patents Examined by Jared Barsky
  • Patent number: 12005057
    Abstract: The present invention provides methods of administering a PARP inhibitor to a cancer patient.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 11, 2024
    Assignee: TESARO, INC.
    Inventors: Mary Lynne Hedley, Robert Martell
  • Patent number: 12006295
    Abstract: An 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: June 11, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11999719
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: June 4, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jing Gao, Yingxia Sang
  • Patent number: 11993554
    Abstract: A compound 3,3?-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol), its synthesis, and its use as an insecticidal agent.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: May 28, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11985973
    Abstract: A composition and method for insect repellent is provided. The composition in one form has on a weight percentage basis 2-4% ?-pinene; 2-4% borneol; 8-10% geraniol; 28-35% linalool; 25-38% linalyl acetate; 1-4% methyl salicylate; 2-4% myrcene; 2-4% para-cymene; 4-8% phellandrene; 1-4% thymol; and 2-4% vanillin. The composition has insect repellent properties.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: May 21, 2024
    Assignee: Global Biolife Inc.
    Inventors: Daryl L. Thompson, Thomas A. Meyer, Nicholas A. Van Rees
  • Patent number: 11986527
    Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 21, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Arturo Angel, Gordon Dow
  • Patent number: 11974992
    Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: May 7, 2024
    Assignees: Neurolixis, The Regents of the University of California
    Inventors: Adrian Newman-Tancredi, Mark A. Varney, Khaleelurrahman Abdulrazak, Xin Tao
  • Patent number: 11975477
    Abstract: The invention generally relates to shape memory films that are tri-functionally crosslinked and that comprise multiple, non-terminal, phenylethynyl moieties. In addition, the present invention relates methods of fabricating such films. Due to the improved properties of such SMPs, the SMP designer can program in to the SMP thermomechanical property enhancements that make the SMP suitable, among other things, for advanced sensors, high temperature actuators, responder matrix materials and heat responsive packaging.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: May 7, 2024
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Loon-Seng Tan, David H. Wang, Zhenning Yu
  • Patent number: 11964978
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: April 23, 2024
    Assignee: PFIZER INC.
    Inventors: Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes
  • Patent number: 11957759
    Abstract: Provided herein are bifunctional compounds having the chemical structure I: PTM-L-CLM??(I): or pharmaceutically acceptable salts thereof, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF) and are useful in the treatment of a variety of Raf mediated conditions or diseases, such as cancer, specifically lung cancer, skin cancer, or colorectal cancer.
    Type: Grant
    Filed: September 7, 2023
    Date of Patent: April 16, 2024
    Assignee: Arvinas Operations, Inc.
    Inventor: Keith R. Hornberger
  • Patent number: 11957753
    Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: April 16, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Arturo Angel, Gordon Dow
  • Patent number: 11951147
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 9, 2024
    Assignee: MEDIVIR AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Patent number: 11952377
    Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • Patent number: 11944634
    Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: April 2, 2024
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: David C. Griffith, Serge Boyer, Scott Hecker, Michael N. Dudley
  • Patent number: 11931347
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: March 19, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Scott Moe
  • Patent number: 11925644
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 12, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz
  • Patent number: 11911366
    Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 27, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hidetoshi Shimizu, Yoshinobu Nakamaru, Yukiko Nishimura
  • Patent number: 11897851
    Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: February 13, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Hui Lei, Haizhen Zhang, Xichen Lin, Andrew Jennings
  • Patent number: 11891353
    Abstract: A compound 3,3?-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol), its synthesis, and its use as an insecticidal agent.
    Type: Grant
    Filed: August 28, 2023
    Date of Patent: February 6, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd Ellateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11883505
    Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: January 30, 2024
    Assignees: CASE WESTERN RESERVE UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Nicole F. Steinmetz, Stephen J. Lippard, Anna Czapar, Yaorong Zheng